Evidence map›Paper›PMID 34774569›Full record

ArticleJournal of molecular biology2022

Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Morgan E Meissner, Nora A Willkomm, Jamie Lucas, William G Arndt, Sarah F Aitken, Emily J Julik, Sunanda Baliga, Louis M Mansky

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Morgan E MeissnerInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Nora A WillkommInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Jamie LucasInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
William G ArndtInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Sarah F AitkenInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Emily J JulikInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Sunanda BaligaInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA.
Louis M ManskyInstitute for Molecular Virology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Division of Basic Sciences, School of Dentistry, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Masonic Cancer Center, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA; Dept. of Microbiology & Immunology, University of Minnesota - Twin Cities, Minneapolis, MN 55455 USA. Electronic address: mansky@umn.edu.
University of Minnesota · US

Funding

TRAINING-PULMONARY CELL &MOLECULAR BIOLOGY &PHYSIOLOGYT32HL007741 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DUDLEY, R. ADAMS, INGBAR, DAVID H · 1994 to 2023
$13.9M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
HIV Gag lattice morphology and particle biogenesisR01AI150468 · NIAID · UNIVERSITY OF MINNESOTA · PI MANSKY, LOUIS M., MUELLER, JOACHIM D · 2019 to 2020
$1.2M
Analysis of human retrovirus particle assembly sitesF30DE031829 · NIDCR · UNIVERSITY OF MINNESOTA · PI WILLKOMM, NORA · 2021 to 2024
$214k
NHLBI NIH HHS T32 HL007741NIAID NIH HHS R01 AI150468NIAID NIH HHS T32 AI083196NIDCR NIH HHS F30 DE031829
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) mutagenesis is driven by a variety of internal and external sources, including the host APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypetide-like 3; A3) family of mutagenesis factors, which catalyze G-to-A transition mutations during virus replication. HIV-2 replication is characterized by a relative lack of G-to-A mutations, suggesting infrequent mutagenesis by A3 proteins. To date, the activity of the A3 repertoire against HIV-2 has remained largely uncharacterized, and the mutagenic activity of these proteins against HIV-2 remains to be elucidated. In this study, we provide the first comprehensive characterization of the restrictive capacity of A3 proteins against HIV-2 in cell culture using a dual fluorescent reporter HIV-2 vector virus. We found that A3F, A3G, and A3H restricted HIV-2 infectivity in the absence of Vif and were associated with significant increases in the frequency of viral mutants. These proteins increased the frequency of G-to-A mutations within the proviruses of infected cells as well. A3G and A3H also reduced HIV-2 infectivity via inhibition of reverse transcription and the accumulation of DNA products during replication. In contrast, A3D did not exhibit any restrictive activity against HIV-2, even at higher expression levels. Taken together, these results provide evidence that A3F, A3G, and A3H, but not A3D, are capable of HIV-2 restriction. Differences in A3-mediated restriction of HIV-1 and HIV-2 may serve to provide new insights in the observed mutation profiles of these viruses.

Indexed as

HIV-2AminohydrolasesAPOBEC-3G DeaminaseCytidine DeaminaseCytosine DeaminaseGene ExpressionHIV InfectionsHumansMutationVirus ReplicationAminohydrolasesAPOBEC3F protein, humanAPOBEC-3G DeaminaseAPOBEC3G protein, humanAPOBEC3H protein, humanCytidine DeaminaseCytosine Deaminasecytidine deaminaselentivirusmutagenesisrestriction factorretrovirus

Identifiers

PMID34774569
PMCPMC8752514
OpenAlexW3213769530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.